SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-005147 to Scorpius Holdings, Inc. (SCPX) (CIK 0001476963) (SCPX)

Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)
Date: May 6, 2024 · CIK: 0001476963 · Accession: 0000000000-24-005147

AI Filing Summary & Sentiment

File numbers found in text: 333-279092

Date
May 6, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Scorpius Holdings, Inc. (SCPX) (CIK 0001476963)

Letter

United States securities and exchange commission logo May 6, 2024 Jeffrey Wolf Chief Executive Officer Scorpius Holdings, Inc. 627 Davis Drive, Suite 300 Morrisville, North Carolina 27560 Re:Scorpius Holdings, Inc. Registration Statement on Form S-1 Filed May 3, 2024 File No. 333-279092 Dear Jeffrey Wolf: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq.

Show Raw Text
United States securities and exchange commission logo
May 6, 2024
Jeffrey Wolf
Chief Executive Officer
Scorpius Holdings, Inc.
627 Davis Drive, Suite 300
Morrisville, North Carolina 27560
Re:Scorpius Holdings, Inc.
Registration Statement on Form S-1
Filed May 3, 2024
File No. 333-279092
Dear Jeffrey Wolf:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Leslie Marlow, Esq.